When Alois Alzheimer in 1906 presented the first case report on the neurodegenerative disorder that now (in)famously bears his name, Alzheimer's disease (AD) was thought to be a rare, noninherited, and sporadic condition. Now, a hundred years later, it has reached epidemic proportions, thereby rapidly transforming itself into a major socioeconomic problem. The main reason for this lies in the increase in average human life expectancy in Western countries, from approximately 47 years in 1906 to 77 years today. Caused by this shift in longevity, the number of late-onset cases, i.e., those that clinically manifest themselves beyond the age of 65, has by far eclipsed the much rarer and often familial early-onset cases.
When Alzheimer first examined the brain of his ''index'' patient to search for a morphological cause for the profound dementia and aberrant behavior that Auguste D. had displayed during the last years of her life, he observed and documented the ''hallmark'' histopathological changes that to this day form the pillars of postmortem diagnosis of AD: (1) a prominent accumulation of amyloid plaques, which, as we now know, are triggered by the aggregation of the amyloid b protein (Ab), a cleavage product of the amyloid precursor protein (APP), and (2) the neurofibrillary tangles, which consist mainly of aggregated forms of the microtubule stabilizing protein tau.
Over 70 years later, in 1984, George Glenner and colleagues eventually purified and sequenced the Ab peptide. In their initial description, they noted that this protein ''may provide a diagnostic test for Alzheimer's disease and a means to understand its pathogenesis'' (Glenner and Wong, 1984) . Besides setting the stage for the ''amyloid hypothesis,'' Glenner's sequence of the Ab peptide opened the door to the cloning of the precursor protein from which it is derived, which in turn soon led to the identification of the first dominant mutation in APP as a cause of familial early-onset AD (Goate et al., 1991) . Further support for the pivotal role of Ab in the pathogenesis of AD came from the genetic and biochemical identification of two intramembraneous proteases that where found to mediate the ultimate cleavage step that releases the Ab peptide from APP. Numerous missense mutations have also been found in these proteases, now known as presenilins 1 and 2, that cause vicious and high-penetrant forms of familial early-onset AD (reviewed in Selkoe and Podlisny, 2002) .
Thus, APP and the presenilins form a classic substrate-enzyme relationship that is responsible for producing the peptide that makes up the pathologic amyloid deposits; taken together, this genetic and biochemical evidence overwhelmingly points to a pivotal function of the Ab-generating machinery that must be part of the disease-causing mechanism. However, most AD cases are of the nonfamilial kind that manifests itself late in life, and these are typically not caused by or associated with mutations in the APP and presenilin genes. Indeed, the most powerful and undisputed ''late-onset AD (LOAD) gene'' is apolipoprotein E (ApoE), specifically the presence of the common 34 isoform, which increases the relative risk in a dose-dependent manner (Corder et al., 1993 ). Yet, ApoE has no obvious structural or functional relationship with the early-onset genes or with the Ab-generating machinery, and the mechanisms by which ApoE4, either directly or indirectly (reviewed in Herz and Chen, 2006; Mahley et al., 2006) , promotes the disease process have not been unequivocally resolved.
Numerous other AD susceptibility genes and quantitative trait loci (Kehoe et al., 1999) have been proposed over the last decade (reviewed in Bertram et al., 2007) , but their relative contributions and significance have frequently come under debate, and few of these candidates have known functions that would implicate them directly in Ab generation. This has revealed, however, that AD, and especially the late-onset form, is in fact a highly complex genetic syndrome for which we still lack sufficient understanding of the underlying molecular mechanisms that alter neuronal cell biology and cause the premature loss of synapses and neurons.
This considerable genetic complexity, combined with the imperfect histopathological correlation of plaque deposition on one hand and neuronal loss and dementia on the other, has raised a ''chicken and egg'' question and fueled a-sometimes furiousdebate in the field: are the plaques themselves primarily responsible for the manifestation of the disease or is it the disruption of more fundamental cellular functions that, when impaired, send the neuron on its way to death, while promoting plaque formation in the process? Clearly, APP processing and Ab generation must play a crucial part in this, since many other neurodegenerative diseases do not exhibit the distinct AD amyloid pathology, so impending neuronal demise alone does not suffice.
Progress in our understanding of this central question has been hampered by our lack of knowledge of what the physiological functions of APP actually are, and this has led several groups to consider alternative mechanisms by which the Ab peptide might act on neurons. Some have recently begun to focus on possible direct effects of Ab on synaptic neurotransmission and glutamate receptor activity (Walsh et al., 2002; Kamenetz et al., 2003) . The findings that are now emerging from these studies reveal novel mechanisms by which Ab might directly control synaptic plasticity, with potential consequences for synaptic stability and survival. These results also point toward exciting, new, and plausible mechanisms by which the effect of ApoE, possibly acting through ApoE receptor-mediated control of NMDA receptor activity, might converge with the signal input provided by the Ab peptide directly at the level of the synapse (reviewed in Herz and Chen, 2006) .
Another potential mechanism by which APP might affect neuronal functions is through its intracellular domain (ICD). There are three APP family members in mammalian species, but only APP produces the Ab peptide. Mice lacking all three genes show greatly reduced viability and exhibit brain developmental abnormalities that resemble lissencephaly (Herms et al., 2004) , suggesting that the APP family has fundamental roles in brain development, potentially involving the regulation of cell adhesion. Interestingly, mice lacking FE65 and FE65-L1, two members of a family of three cytoplasmic scaffolding proteins, show a strikingly similar phenotype (Guenette et al., 2006) . Furthermore, the lossof-function phenotypes of apl-1 and feh-1, the sole orthologs of the APP and FE65 family members in the simple nematode Caenorhabditis elegans, also mirror each other, suggesting that the intracellular domain (ICD) of APP, to which the FE65 proteins bind, may form a physiologically important complex with FE65 family members.
Release of the ICD is necessarily coupled to the generation of the Ab peptide, since the ultimate cleavage of APP by g-secretase, i.e., a presenilin containing complex, results in an equimolar production of either peptide. Moreover, presenilins not only cleave APP, but also a series of other membrane proteins, most notably Notch, for which an essential role of its ICD in the regulation of gene transcription had been well established. These insights prompted Cao and Sü dhof (Cao and Sü dhof, 2001 ) to investigate, whether the ICD of APP (AICD) may also be involved in transcriptional regulation. Using reporter assays, they found indeed that release of the AICD from the plasma membrane could stimulate reporter gene activation. This was dependent upon the activation and release of FE65 at the plasma membrane and on the recruitment of Tip60, a transcriptional activator, by this scaffolding protein. Glass, Rosenfeld, and colleagues subsequently suggested that the AICD/FE65/Tip60 complex might be involved in the regulation of NF-kB target genes, through exchange of a nuclear receptor corepressor complex (Baek et al., 2002) .
Building on these initial reports, Pardossi-Piquard et al. (Pardossi-Piquard et al., 2005) searched for target genes that might be controlled by presenilinmediated cleavage of APP family members and AICD release. In their study, published in Neuron in 2005, they focused on neprilysin, an Ab-degrading enzyme. The work was based on the rationale that this protease might be a plausible target for AICD/ FE65/Tip60-mediated transcriptional regulation, since such an intrinsic feedback mechanism would automatically ensure that Ab concentrations would be maintained within narrow parameters, thereby preventing Ab-mediated cellular toxicity and amyloid formation.
The findings of the Pardossi-Piquard et al. study have recently been challenged. A study conducted independently in Bart de Strooper's laboratory (Hebert et al., 2006) , did not find convincing evidence for an AICD-dependent mechanism by which the expression of a number of previously suggested target genes, including neprilysin, might be transcriptionally regulated. These conclusions are echoed in the Correspondence by Chen and Selkoe (this issue of Neuron), who also raise questions about the data in the original Pardossi-Piquard et al. study and about the evidence supporting a presenilin and AICD-dependent feedback mechanism that controls the degradation of Ab through neprilysin. In their Response, PardossiPiquard and colleagues (this issue of Neuron) point to a series of findings presented by Chen and Selkoe that lend support to several important elements published in their initial report, most notably the virtual absence of neprilysin expression in presenilin 1 and 2 double-deficient cells. This remarkable reduction of expression was also observed in the absence of APP and APLP-2 (Pardossi- Piquard et al., 2005) . In further support of the conclusions they now also show preliminary data from FE65/AICD double-transgenic mice that reveal significantly increased neprilysin expression in brain.
What might be the reasons for such seemingly diametrically opposite conclusions and conflicting results? Part of this discrepancy might be explainable by differences in experimental approaches and clonal variations or origin of the cell lines that were used by the different groups, as well as diverging opinions about the significance and interpretation of the strength of specific pieces of experimental evidence. However, the conceptual and biomedical importance of the mechanism Pardossi-Piquard and colleagues have proposed will ensure that the current controversy will be resolved quickly and in due course through independent work of other laboratories that will build on these findings and conclusions.
Some things nevertheless are certain: (1) our mechanistic understanding of the pathogenesis of AD is rudimentary at best and much remains to be discovered, (2) this field is not likely to get boring tomorrow, and (3) even now, over 90 years after his death, Alois Alzheimer continues to watch out that he will not be forgotten for years to come. Pardossi-Piquard et al. (2005) recently reported that the processing of APP by the presenilin/g-secretase complex to release the APP intracellular domain (AICD) allows the latter to upregulate the cellular expression of neprilysin. The authors emphasized the biological elegance of this novel feedback mechanism in that a by-product (AICD) of thegeneration of amyloid b protein (Ab) increases the levels of a protease (neprilysin) that can then degrade Ab. Here, we report that experiments similar to those of Pardossi-Piquard et al. did not provide evidence that neprilysin levels and activity are regulated by presenilin-mediated processing of APP.
Results

Neprilysin Protein Levels Do Not Correlate with Presenilin Genotype and Are Not Rescued by Presenilin Expression
To examine whether neprilysin protein levels are regulated by presenilin (PS) expression as reported (PardossiPiquard et al., 2005) , mouse embryonic stem cells genetically devoid of both PS1 and PS2 (BD8 cells) were analyzed by Western blotting (see Methods in the Supplemental Data available online). Cells were harvested in Tris buffer containing either no detergent, 0.5% Triton X-100, or 1% NP40 and blotted for neprilysin, APP C-terminal fragments (CTFs), and GAPDH. The lack of PS expression resulted in no significant reduction in neprilysin levels in cells harvested in either Tris buffer or Tris-1% NP40 buffer compared to identically prepared wt embryonic stem cells (PBD8) ( Figure 1A ). In cells harvested in Tris-0.5% Triton buffer, we observed either a modest (Figure 1A) or no ( Figure S1A ) reduction in neprilysin levels. To determine whether introduction of presenilin could rescue this variable and modest decrease, the BD8 cells were transiently transfected with PS1, PS2, or both. Transfection of PS resulted in the rescue of g-secretase complex formation (PS endoproteolysis and enhanced nicastrin maturation) and activity (reduction in the elevated APP CTFs) in the BD8 cells ( Figure 1B) (Chen et al., 2003; Kimberly et al., 2002; Leem et al., 2002) . However, neprilysin levels were unchanged ( Figure 1B) . When quantified, neprilysin levels (versus control) were 93.7% ± 0.2% (SEM), 105.7% ± 1.1%, and 98.6% ± 18.3% for cells transfected with PS1, PS2, or both, respectively (p > 0.05 in all cases) ( Figure S1B ).
Next, we examined primary mouse embryonic fibroblasts (MEFs) cultured from mice genetically lacking PS1, PS2, or both, using the same source as those analyzed by Pardossi-Piquard et al. (Herreman et al., 2003) . Neprilysin levels were reduced in PS dKO cells as compared to wt ( Figure 1C ). Because PS1 confers the predominant PS activity found in g-secretase, it would be
